The Transcode Therapeutics Inc (NASDAQ: RNAZ) stock price rallied 78.5% after announcing that it had withdrawn the registration statement it had filed with the US Securities and Exchange Commission (SEC).
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
The company had planned to raise funds by selling 12.5 million units of its common stock. The company had not agreed on the pricing of the new shares but noted that its stock had been trading at about $0.48 at the time.
Top Broker Recommendation
- BlackBull 26,000+ Shares, Options, ETFs, Bonds, and other underlying assets – Read our Review
- Admiral Markets More than 4500 stocks & over 200 ETFs available to invest in – Read our Review
- Hargreaves Lansdown The company's website is easily understandable and accessible to a wide range of customers – Read our Review
- eToro Wide range of instruments available to trade – Read our Review
- IG Top-tier regulation – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
Therefore, the price offered to the participating investors would have been around this average. Today’s announcement triggered a rally as investor interest in the company skyrocketed. RNAZ shares rallied after the registration statement's withdrawal, indicating that the company is in a robust financial position and does not need to raise funds urgently.
Some of the latest announcements from the company include the submission of an exploratory Investigational New Drug, eIND, application to the U.S. Food and Drug Administration, FDA, for a planned First-in-Human Phase 0 clinical trial.
Transcode Therapeutics intends to conduct a clinical trial to evaluate its lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. The drug is designed to inhibit the pro-metastatic RNA, microRNA-10b, which is the master regulator of metastasis in several advanced solid tumors.
The company has also released the preclinical trial data of its immunotherapy candidate, TTX-siPDL1, in pancreatic adenocarcinoma. The study showed that combining TTX-siPDL1 with the standard-of-care chemotherapeutic, gemcitabine resulted in tumor volumes that were 25% of those in untreated animals.
The study showed that 75% of animals treated with the combination were alive after five weeks of treatment compared to 25% of those on gemcitabine alone. This was the second drug candidate developed by TransCode's platform to show positive preclinical results in pancreatic cancer.
Investor interest in Transcode Therapeutics stock remains high as shown by the over 4.76 million shares that changed hands during the premarket trading session.
*This is not investment advice.
Transcode Therapeutics (RNAZ) stock price.
The Transcode Therapeutics (RNAZ) stock price rallied 78.47% to trade at $0.75, rising from Tuesday’s closing price of $0.4198.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.